Suppr超能文献

确定体细胞肿瘤突变是否可靶向治疗以及获得靶向治疗的选择。

Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.

机构信息

American Society of Clinical Oncology.

出版信息

J Oncol Pract. 2019 Nov;15(11):575-583. doi: 10.1200/JOP.19.00262. Epub 2019 Aug 6.

Abstract

Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usually requires verification through molecular testing that the patient's tumor harbors the molecular biomarker that is the target of the drug or is predictive of treatment benefit. Genomic mutations may be clinically actionable if they are associated with response or resistance to a potential therapy. If a genomic test reveals an actionable alteration, there are several options for accessing the targeted therapy. This article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest.

摘要

靶向癌症疗法是指通过阻断或干扰癌细胞内特定的分子途径来影响癌细胞生长的药物和生物制剂。靶向药物的使用通常需要通过分子检测来验证患者的肿瘤是否携带有药物作用靶点的分子生物标志物,或者是否对治疗有预测作用。如果基因组突变与对潜在治疗方法的反应或耐药性相关,则可能具有临床意义。如果基因组检测显示出可采取行动的改变,则有几种选择可以获得靶向治疗。本文旨在帮助临床医生确定肿瘤突变是否可以用已上市或正在研究的药物或生物制品进行潜在治疗,并提供有关如何获得感兴趣的产品的指导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验